Moderna and Merck announced the success of their mRNA vaccine in a melanoma study
Moderna and Merck announced that a personalized mRNA cancer vaccine, when combined with Keytruda, slowed the recurrence of melanoma and its spread to other parts of the body in a late-stage clinical trial, according to STAT News.
The trial was conducted among patients with adjuvant melanoma—that is, those whose tumors had been surgically removed. The study used the personalized vaccine intismeran in combination with Keytruda, a drug developed by Merck.
For more breaking news, follow the UA.News Telegram channel.
According to the publication, this is the first randomized Phase III clinical trial designed to definitively confirm the benefits of so-called neoantigen vaccines in the treatment of cancer. Such vaccines have long been considered a potential method of cancer therapy.
Moderna and Merck did not release detailed trial data immediately after announcing the results. If the results are confirmed, this approach could open up possibilities for use in other types of cancer and demonstrate the potential of the mRNA platform for developing vaccines and therapeutic agents.
